HOME >> BIOLOGY >> NEWS
DFG establishes first German-Sino Research Training Group

fic Category, Humboldt University of Berlin
  • Paths of Routine Processes, Free University in Berlin
  • Non-equilibrium Phenomena in Low-temperature Plasmas: Diagnosis Modelling Applications, Ruhr University of Bochum
  • Presentation Theory and its Applications in Mathematics and Physics, Bergische University of Wuppertal
  • Signaling Mechanisms in Lung Physiology and Disease, Liebig University of Giessen
  • History and Culture of Metropolises of the 20th Century, Technical University of Berlin, Humboldt University of Berlin, Free University in Berlin
  • Political Communication from Antiquity to the 20th Century, University of Frankfurt am Main
  • Archive, Power, Knowledge Organising, Controlling, Destroying Stocks of Knowledge from Antiquity to the Present, University of Bielefeld
  • Catalysts and Catalytic Reactions for Organic Systems, University of Freiburg
  • Development and Application of Intelligent Detectors, University of Heidelberg
  • Medial Historiographies, Bauhaus University of Weimar
  • Modelling the Flow of Materials and Production Systems for the Sustained
  • Utilisation of Resources in Intensive Agronomical and Market Gardening Systems in the North-Chinese Lowland Plain, University of Hohenheim

Since 1990, the DFG has been funding Research Training Groups for outstanding doctoral students in all scientific disciplines. Under the guidance of well-qualified professors in research and teaching, 15 to 25 of them work in an interdisciplinary research and study programme. At present, about six per cent of all doctoral students in Germany complete their doctorates in Research Training Groups. Graduates from Research Training Groups are generally more extensively qualified and, on average, two years younger tha
'"/>

Contact: Dr. Jrg Schneider
joerg.schneider@dfg.de
49-228-885-2424
Deutsche Forschungsgemeinschaft
28-Apr-2004


Page: 1 2 3 4

Related biology news :

1. Tufts University establishes $4 million dollar tissue engineering resource center
2. DFG establishes 14 new research units
3. NIH establishes Rare Diseases Clinical Research Network
4. $8 million grant establishes program to uncover genetics of asthma
5. Hemocellular Therapeutics establishes licensing agreement with UNC, ECU
6. New research establishes genetic associations in hepatitis C
7. NSF establishes center for biophotonics at UC Davis
8. NIH funding establishes a chimpanzee sanctuary
9. Guyana establishes its first conservation concession
10. USDA establishes Honeybee Genetics and IPM Center
11. Scientist finds genetic clues to Alzheimers, establishes DNA bank for future studies

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: DFG establishes first German Sino Research Training Group

(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
(Date:8/5/2015)... MOUNTAIN VIEW, Calif. , Aug. 5, 2015 /PRNewswire/ ... it exhibits continuous growth in applications, penetration into newer ... year after year. The global biosensors space has seen ... having exited the market so far. (Photo ... from Frost & Sullivan, Analysis of the Global ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
(Date:8/28/2015)... -- According to a new market research ... Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem Cells, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020 from USD 2,150.48 Million in 2015, ... 2020. Browse 74 Tables and 95 ...
(Date:8/28/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, ... June 30, 2015, corporate highlights, and near-term milestones.  ... available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment for ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... venture capital funds, investment firms and animal health companies to hear from animal ... $160 million. Several have also received licensing agreements or distribution contracts. This ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
Breaking Biology Technology:Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
Cached News: